REGULATORY
MHLW to Conduct Hearings over CASE-J Study, Take “Appropriate Action” against Takeda: Minister
The Ministry of Health, Labor and Welfare (MHLW) will conduct hearings with stakeholders over a clinical trial of Takeda Pharmaceutical’s hypertension drug Blopress (candesartan), Minister Norihisa Tamura said on June 26. The comment came after a third-party investigation concluded last…
To read the full story
Related Article
REGULATORY
- Japan Diet Begins Deliberations on Immunization Act Revision
June 25, 2026
- US Opens Probe into German Drug Pricing Policies; Could Japan Be Next?
June 24, 2026
- Japan Awards Sakigake Tag to AbbVie’s Bispecific Etentamig
June 24, 2026
- Japan Grants Orphan Status to Vanda, Quoin Drugs, and Lots More
June 24, 2026
- Carvykti Earlier Use Up for Japan Panel Review on June 29
June 23, 2026
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…





